Homepage
Author:
Caribou Biosciences, Inc.
Posted Date:
June 11, 2026
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences, Inc.
June 11, 2026
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
Caribou Biosciences, Inc.
June 11, 2026
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Caribou Biosciences, Inc.
May 27, 2026
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
Caribou Biosciences, Inc.
May 13, 2026
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
Caribou Biosciences, Inc.
May 12, 2026
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Caribou Biosciences, Inc.
May 7, 2026
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
Caribou Biosciences, Inc.
May 5, 2026
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Caribou Biosciences, Inc.
March 31, 2026
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Caribou Biosciences, Inc.
March 5, 2026
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences, Inc.
February 12, 2026
1
2
Next
